Tedesco Kerry L, Rybak Michael J
Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, School of Medicine, Wayne State University, Detroit, MI 48201, USA.
Pharmacotherapy. 2004 Jan;24(1):41-57. doi: 10.1592/phco.24.1.41.34802.
Daptomycin, the first in a class of agents known as lipopeptides, is a novel antimicrobial agent used for the treatment of gram-positive infections. The compound has a distinctive mechanism of action that exerts its bactericidal activity by disrupting plasma membrane function without penetrating into the cytoplasm. The agent has received much interest because of its activity against multidrug-resistant, gram-positive bacteria such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, and glycopeptide-intermediate and -resistant S. aureus. Daptomycin demonstrates concentration-dependent killing and is eliminated primarily by glomerular filtration. It was approved in September 2003 for the treatment of complicated skin and soft tissue infections. It has a safety profile similar to other agents commonly administered to treat gram-positive infections. Daptomycin is a welcome addition to the antimicrobial armamentarium for the treatment of bacterial infections. Further clinical experience with this compound will help define its role in the treatment of resistant gram-positive organisms.
达托霉素是脂肽类药物中的首个药物，是一种用于治疗革兰氏阳性菌感染的新型抗菌剂。该化合物具有独特的作用机制，通过破坏细胞膜功能发挥杀菌活性，而不穿透进入细胞质。由于其对多重耐药革兰氏阳性菌如耐甲氧西林金黄色葡萄球菌、耐万古霉素肠球菌以及糖肽类中介及耐药金黄色葡萄球菌具有活性，该药物备受关注。达托霉素显示出浓度依赖性杀菌作用，主要通过肾小球滤过消除。它于2003年9月被批准用于治疗复杂性皮肤和软组织感染。其安全性与常用于治疗革兰氏阳性菌感染的其他药物相似。达托霉素是抗菌药物库中用于治疗细菌感染的一个受欢迎的补充药物。对该化合物的进一步临床经验将有助于明确其在治疗耐药革兰氏阳性菌中的作用。
